转化医学：我们要在弯道上超车

JOEL

3 p3 V- k: }2 Y3 A
It is better to get the basic "translation medicine" well-clear primarily.   p: x/ U2 l, R) r. y0 e
什麽是“轉化醫學”？1 r- R& w9 P+ n/ \8 j* t- Y
什麽是”轉化醫學研究“？
/ _9 c& r2 x# I# [7 R轉化醫學研究中心，使命是什麽？運作策略和模式是什麽？3 R9 w; O7 w' c9 y+ ^

7 A) {; E/ V, H# h* P& {5 iThen, TM is not a fashion. Certainly NIH has had its well-built blue-print / strategy / methodology with its creative ideas on its TM.
5 m7 g  S4 S7 m# j8 u% S通俗地講， TM  更多関注的是策略，就是保障前沿 biotechnology 安全地，有效地，合法地， 符合國際供認的倫理規范地， 因而成就高效率的临床常規應用。其核心使命立即聚焦在biotechnology 硏發的 Clinical Phase III， 即III 期臨床實驗階段. 雖已進入临床但它仍然還是高端的研究階段。常識： 動物模型有時与人體應用會有惊人的差异。 因此，TM 研究必需實行國家入行嚴控，顯然不可遍地開花誰都可以做。9 H& n, A) G6 g' M0 V% x

' B& F; w  \# F5 A) ]2 |5 xActually, TM as strictly managed operation is just a best healing for the chaotic situations of the SCR field, which，like so many criminals---quacks acting in the gray-zone under the umbrella, have blindly applied the so-called biotech into the clinical routine without any confirmed reference of the safty but just based on the QUACK'S THEORY that "I think so" in the name of annotation.
8 [1 d, b; k. \% ]+ m& t
/ S0 T7 v, k/ f' Q6 JI agree with most of the friends,  the biotech field in 貴國 China has been crying for:  1, bio-law and, 2, strictly controlled phase III, i.e. clinical trials ---this is the key mission for TM in China. Without a thorough solution for these two pre-conditions all the talking is just a talk-show.  9 m# K/ R2 B" W# C

0 q$ N" f4 Z+ w8 u) H$ u1 G& g. f

JOEL

回复 wnavy200299 的帖子" Q2 s( p4 a& V

5 R3 y. O7 D" |1 b
( Q5 j4 B  o7 _1 W& S7 ]Bravo! a vivid and in-depth analysis with insight.